(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 76.39%.
Kyntra Bio's earnings in 2026 is $183,452,000.On average, 4 Wall Street analysts forecast KYNB's earnings for 2026 to be -$55,889,918, with the lowest KYNB earnings forecast at -$62,661,069, and the highest KYNB earnings forecast at -$47,930,619. On average, 4 Wall Street analysts forecast KYNB's earnings for 2027 to be -$42,309,576, with the lowest KYNB earnings forecast at -$45,766,376, and the highest KYNB earnings forecast at -$38,072,548.
In 2028, KYNB is forecast to generate -$37,624,565 in earnings, with the lowest earnings forecast at -$44,893,880 and the highest earnings forecast at -$29,361,753.